Summarized by Masters of Longevity from PR Newswire.
A biotech news item about a company filing to begin first-in-human testing of an investigational siRNA therapy; it previews a clinical development update and what readers can expect about study aims and rationale.
Key Takeaways
- Ribo submitted a Clinical Trial Application in the EU for its siRNA candidate RBD3133 targeting INHBE.
- The planned Phase I study is randomized and placebo controlled to assess safety, tolerability, PK, and PD after subcutaneous dosing.
- Human genetic data linking INHBE loss-of-function to healthier fat distribution and lower cardiometabolic risk supported the target choice.
